Skip to search formSkip to main contentSkip to account menu

BMS-833923

Known as: Smoothened Antagonist BMS-833923, XL139 
An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesQuinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 3631: A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks
Ovarian cancer (OVCA) is the deadliest of all the reproductive cancers, affecting over 22,000 lives of women annually in the USA… 
2011
2011
A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,
Abstract 3993 Background: Aberrant hedgehog (HH) pathway signaling has been suggested to play a role in the development and… 
2011
2011
A novel hedgehog pathway smoothened inhibitor (BMS-833923) demonstrates in vitro synergy with carboplatin in ovarian cancer cells
2009
2009
Abstract C18: Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers
Background: Inhibition of the Hedgehog pathway using Smoothened antagonists is emerging as a promising targeted therapy for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)